Geneva – The World Health Organization (WHO) in a recent statement has said that the AstraZeneca Covid-19 vaccine has great benefits, tremendous potential to prevent infections and reduce deaths across the world. Based on available data the review team found no increased risk of blood clotting conditions in people who received the AstraZeneca-Oxford vaccine. The Global Advisory Committee on Vaccine Safety (GACVS) Covid-19 and reviewed clinical trial data and reports based on safety data from Europe, the UK, India, and Vigibase. It said the data does not suggest an overall increase in clotting conditions such as deep venous thrombosis or pulmonary embolism following administration of Covid-19 vaccines. It added: “Reported rates of thromboembolic events after Covid-19 vaccines are in line with the expected number of diagnoses of these conditions. Both conditions occur naturally and are not uncommon. They also occur as a result of Covid-19. The observed rates have been fewer than expected for such events. The sub-committee will continue to review the safety data from all Covid-19 vaccines and update any advice as necessary.” So far, over 20 million doses of the AstraZeneca vaccine have been administered in Europe.